INKT

Mink Therapeutics Stock Analysis

AI Rating

Good
  • Quality5/10
  • Growth↑ 7/10
  • Value↑ 5/10
Mink Therapeutics sales and earnings growth
INKT Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -2.45%
  • FCF Y/Y↑ 37.99%
Mink Therapeutics gross and profit margin trends
INKT Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↑ 244.18%
Mink Therapeutics net debt vs free cash flow
INKT Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Mink Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks